Answers are grounded in this paper and cite their sources.
Background Triple antithrombotic therapy (TAT) with aspirin, a P2Y12 inhibitor, and oral anticoagulation in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) raises concerns about increased bleeding. Regimens incorporating more potent P2Y12 inhibitors over clopidogrel have not been investigated adequately.
No takes yet. Share an insight, caveat, or question.
Sammut et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: